199868-84-3

Basic information

• Product Name: 2-(2-HYDROXY-1-PHENYLETHYL)-1-ISOINDOLINONE
• Synonyms: 2-(2-HYDROXY-1-PHENYLETHYL)-1-ISOINDOLINONE;2-(2-hydroxy-1-phenylethyl)-2,3-dihydro-1H-isoindol-1-one
• CAS NO: 199868-84-3
• Molecular Formula: C₁₆H₁₅NO₂
• Molecular Weight: 253.3
• Mol File: 199868-84-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 472.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.271±0.06 g/cm3(Predicted)
• PKA: 14.19±0.10(Predicted)
• CAS DataBase Reference: 2-(2-HYDROXY-1-PHENYLETHYL)-1-ISOINDOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-HYDROXY-1-PHENYLETHYL)-1-ISOINDOLINONE(199868-84-3)
• EPA Substance Registry System: 2-(2-HYDROXY-1-PHENYLETHYL)-1-ISOINDOLINONE(199868-84-3)

Safety Data

• Hazardous Substances Data: 199868-84-3(Hazardous Substances Data)

Upstream product

• 96017-07-1 methyl-2-(1-oxoisoindolin-2-yl)-2-phenylacetate 
• 37167-62-7 bromo-phenyl-acetic acid methyl ester 
• 101-41-7 benzeneacetic acid methyl ester 
• 20989-17-7 Phenylglycinol 
• 119-67-5 o-carboxybenzaldehyde 
• 199868-83-2 3-Phenyl-2,3-dihydro-9bH-oxazolo[2,3-a]isoindol-5-one 

Downstream Products

• 98-86-2 acetophenone 
• 55740-90-4 2-(1-phenylvinyl)isoindolin-1-one 

Relevant articles and documents

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.